BridgeMD
New treatment option for PreDiabetes
Official title The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
ClinicalTrials.gov ID: NCT06967558
What this study is testing
What is Exendin 9-39?
Exendin 9-39 is an investigational medicine, being studied as a potential treatment for prediabetes.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 25 to 70. Healthy volunteers may be eligible.
You may be able to join if
- People with stable weight and no history of diabetes.
- Fasting glucose \< 126 mg/dL
- 2hr glucose after 75g OGTT \< 200 mg/dL
You likely can't join if
- Age \ 70 years (to avoid studying people who could have latent type 1 diabetes, or the effects of age extremes in people with normal or impaired...
- HbA1c \> 6.5%
- Use of any glucose-lowering agents including metformin or sulfonylureas.
- For female people: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Active systemic illness or malignancy.
See the full eligibility criteria
- People with stable weight and no history of diabetes.
- Fasting glucose \< 126 mg/dL
- 2hr glucose after 75g OGTT \< 200 mg/dL
- Age \ 70 years (to avoid studying people who could have latent type 1 diabetes, or the effects of age extremes in people with normal or impaired fasting glucose).
- HbA1c \> 6.5%
- Use of any glucose-lowering agents including metformin or sulfonylureas.
- For female people: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
The study team makes the final eligibility decision.
Where it's taking place
- Rochester, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 25 years to 70 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rochester, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.